RT Journal Article
SR Electronic
T1 Rapid waning of protection induced by prior BA.1/BA.2 infection against BA.5 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.08.16.22278820
DO 10.1101/2022.08.16.22278820
A1 Malato, João
A1 Ribeiro, Ruy M.
A1 Fernandes, Eugénia
A1 Leite, Pedro Pinto
A1 Casaca, Pedro
A1 Antunes, Carlos
A1 Fonseca, Válter R.
A1 Gomes, Manuel Carmo
A1 Graca, Luis
YR 2022
UL http://medrxiv.org/content/early/2022/08/17/2022.08.16.22278820.abstract
AB SARS-CoV-2 omicron subvariants BA.1 and BA.2 became dominant in many countries in early 2022. These subvariants are now being displaced by BA.4 and BA.5. While natural infection with BA.1/BA.2 provides some protection against BA.4/BA.5 infection, the duration of this protection remains unknown.We used the national Portuguese COVID-19 registry to investigate the waning of protective immunity conferred by prior BA.1/BA.2 infection towards BA.5. We divided the individuals infected during the period of BA.1/BA.2 dominance (>90% of sample isolates) in successive 15-day intervals and determined the risk of subsequent infection with BA.5 over a fixed period.Compared with uninfected people, one previous infection conferred substantial protection against BA.5 re-infection at 3 months (RR=0.12; 95% CI: 0.11-0.12). However, although still significant, the protection was reduced by two-fold at 5 months post-infection (RR=0.24; 0.23-0.24).These results should be interpreted in the context of vaccine breakthrough infections, as the vaccination coverage in the individuals included in the analyses is >98% since the end of 2021.This waning of protection following BA.1/BA.2 infection highlights the need to assess the stability and durability of immune protection induced with the adapted vaccines (based on BA.1) over time.Competing Interest StatementThe authors have declared no competing interest.Funding StatementParts of this work were funded by the European Union Horizon 2020 research and innovation program (ERA project No 952377 - iSTARS); and Fundacao para a Ciencia e a Tecnologia (FCT, Portugal) through 081_596653860 and PTDC/MAT-APL/31602/2017 and the National Institutes of Health grant R01-AI116868. JM acknowledges funding from FCT, Portugal (grant ref. SFRH/BD/149758/2019).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study design was approved by the Ethics Review Board of the Centro Academico de Medicina de Lisboa.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData from the Portuguese COVID-19 registry (SINAVE) is available upon reasonable request from Direcao Geral de Saude Portugal which curates the registry.